Desmopressin Effective for Treating Nocturia in Adults


Am Fam Physician. 2014 Dec 1;90(11):796a-797.

Clinical Question

Is desmopressin safe and effective in treating adults with nocturia?

Bottom Line

Desmopressin is a safe and effective treatment to offer adults with clinically significant nocturia. The initial starting dose should be 50 to 100 mcg, with lower dosing for the advanced older patient. All patients should be monitored for hyponatremia. (Level of Evidence = 1a)


These investigators searched PubMed and reference lists of included studies, as well as a previous systematic review, for randomized clinical trials that compared desmopressin with placebo in adults with nocturia. Two reviewers independently assessed potential publications for inclusion and methodologic quality, and differences were resolved after a consensus discussion with a third reviewer. Quality was assessed using the standard Cochrane Collaboration bias risk guidelines. Ten articles (N = 2,191) met inclusion criteria, including four studies that used an active run-in period after which patients who experienced adverse events or did not respond to the study drug were excluded. As a result, these four studies were considered at high risk of bias, whereas the remaining six were all assessed as high quality. Outcomes were stratified by dose (less than 100 mcg vs. 100 mcg or greater).

Overall, patients receiving desmopressin experienced a significant decrease in the number of nocturnal voids compared with those taking placebo (0.5 fewer voids; 95% confidence interval, 0.35 to 0.65). The benefit was greater for doses of 100 mcg or higher than for lower doses (0.77 fewer voids vs. 0.3 fewer voids, respectively). The overall results were also homogeneous in the high-dose subgroup. In addition, patients receiving desmopressin experienced significantly increased sleep time compared with control patients (mean = 58 more minutes; 95% confidence interval, 39 to 76). Headaches and hyponatremia were the most commonly reported adverse effects; complications and severe adverse events were rare. There were no differences in results based on sex.

Study design: Meta-analysis (randomized controlled trials)

Funding source: Self-funded or unfunded

Setting: Various (meta-analysis)

Reference: Ebell MH, Radke T, Gardner J. A systematic review of the efficacy and safety of desmopressin for nocturia in adults. J Urol. 2014; 192( 3): 829– 835.

POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP,search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.



Want to use this article elsewhere? Get Permissions

More in AFP

Editor's Collections

Related Content

More in Pubmed


Sep 2021

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article